ALKERMES PLC
NASDAQ: ALKS (Alkermes plc)
Last update: 9 hours ago34.99
-0.41 (-1.16%)
| Previous Close | 35.40 |
| Open | 35.63 |
| Volume | 1,698,539 |
| Avg. Volume (3M) | 2,306,206 |
| Market Cap | 5,831,986,688 |
| Price / Earnings (TTM) | 38.88 |
| Price / Earnings (Forward) | 149.25 |
| Price / Sales | 3.91 |
| Price / Book | 3.12 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2026 |
| Profit Margin | 23.30% |
| Operating Margin (TTM) | 4.50% |
| Diluted EPS (TTM) | 2.10 |
| Quarterly Revenue Growth (YOY) | -12.50% |
| Quarterly Earnings Growth (YOY) | -39.00% |
| Total Debt/Equity (MRQ) | 4.90% |
| Current Ratio (MRQ) | 3.33 |
| Operating Cash Flow (TTM) | 516.83 M |
| Levered Free Cash Flow (TTM) | 429.53 M |
| Return on Assets (TTM) | 11.62% |
| Return on Equity (TTM) | 25.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Alkermes plc | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -4.0 |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.20 |
|
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 1.49% |
| % Held by Institutions | 107.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Gendell Jeffrey L | 31 Dec 2025 | 4,769,357 |
| Weiss Asset Management Lp | 31 Dec 2025 | 4,515,114 |
| Tig Advisors, Llc | 31 Dec 2025 | 3,859,122 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 45.00 (RBC Capital, 28.61%) | Buy |
| 45.00 (Wolfe Research, 28.61%) | Buy | |
| Median | 44.00 (25.75%) | |
| Low | 34.00 (B of A Securities, -2.83%) | Hold |
| Average | 41.75 (19.32%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 31.69 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 26 Feb 2026 | 45.00 (28.61%) | Buy | 30.73 |
| Wells Fargo | 26 Feb 2026 | 43.00 (22.89%) | Buy | 30.73 |
| Wolfe Research | 24 Feb 2026 | 45.00 (28.61%) | Buy | 33.39 |
| B of A Securities | 20 Feb 2026 | 34.00 (-2.83%) | Hold | 31.91 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GAFFIN DAVID JOSEPH | - | 34.17 | -2,034 | -69,502 |
| HOPKINSON CRAIG C. | - | 33.38 | -9,000 | -300,420 |
| Aggregate Net Quantity | -11,034 | |||
| Aggregate Net Value ($) | -369,922 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 33.78 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GAFFIN DAVID JOSEPH | Officer | 04 May 2026 | Automatic sell (-) | 2,034 | 34.17 | 69,502 |
| HOPKINSON CRAIG C. | Officer | 01 May 2026 | Automatic sell (-) | 9,000 | 33.38 | 300,420 |
| HOPKINSON CRAIG C. | Officer | 01 May 2026 | Option execute | 5,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |